Maiwei Biological-B (02493): 9MW5211 injection clinical trial application approved by FDA.

The Zhitong Finance APP News, Maiwei Biosciences-B (02493) announced that the company recently received a "Study May Proceed Notification" issued by the US Food and Drug Administration (FDA). The clinical trial application for the 9MW5211 injection for the treatment of inflammatory bowel disease (IBD) has been officially approved by the FDA. At the same time, clinical trial applications for its use in IBD, multiple sclerosis (MS), and other indications have been accepted by the National Medical Products Administration, and the company is actively advancing other clinical trial applications for different indications.